ClinicalTrials.gg
RecruitingNCT06344338tDCSUpdated Aug 4, 2026

Application of tDCS Stimulation in Controlling Refractory Status Epilepticus

An interventional study of tDCS stimulation and TDCS sham-stimulation in Refractory Status Epilepticus, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 14 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
14 Years to 80 Years
Sex
All
01

Study summary

The purpose of the study is to assess the efficacy and safety of targeting tDCS stimulation for treatment of Refractory status epilepticus

Read the detailed description

After being informed about the study and potential risks, the recruited patients, giving written informed consent, will be determined of the eligibility for study entry. The patients who meet the eligibility requirements will be randomized in a 1:1 ratio to undergo targeting tDCS stimulation (up to 10 times) or sham stimulation.

02

Conditions studied

  • Refractory Status Epilepticus

Browse trials for

03

In context

Status Epilepticus

124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.

This study's planned enrollment of 32 is below the median of 80 across 75 interventional studies indexed under Status Epilepticus.

Browse Status Epilepticus studies →

Lead sponsor

Xuanwu Hospital, Beijing is the lead sponsor of 365 studies on the registry; 231 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 14 and 80 year-old with Gender unlimited,
  • Suitable for EEG monitoring;
  • Clinical diagnosis of status epilepticus (status epilepticus that cannot be controlled by two types of antiepileptic drugs and at least one anesthetic);
  • to participate in this study was obtained from the participants or their surrogates

Exclusion criteria

Exclusion Criteria:

  • Unstable vital signs (systolic blood pressure\<90mmHg, heart rate\<60 beats/min, pulse oxygen saturation\<90%);
  • Having severe skull injury/defect or medical equipment implanted in the head;
  • Pregnancy;
  • With any implantable electronic instrument (including pacemakers, vagus nerve stimulators) or metal implanted devices.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    tDCS treatment group

    In the real tDCS stimulation group, direct cathodal current at 2 mA was delivered by a tDCS device over the seizure onset zone. Anode was on the contralateral forehead. Treatment was for 20 min, repeated twice in a day, then again over the next few days. The maximum number of stimuli required to terminate the status epilepticus should not exceed 10.

    Device: tDCS stimulation

  • Sham comparator
    TDCS sham-stimulation group

    The duration and frequency of tDCS treatments in the sham-stimulation group are the same as those in the treatment group, but the tDCS device is not active during the 20 minutes of sham-stimulation.

    Device: TDCS sham-stimulation

Interventions

  • DevicetDCS stimulation

    In the real-stimulation group, Treatment was for 20 min, repeated twice in a day, then again over the next few days. The maximum number of stimuli required to terminate the status epilepticus should not exceed 10. In the sham-stimulation group, The duration and frequency of tDCS are the same as those in the treatment group, but the tDCS device is not active during the 20 minutes of sham-stimulation

  • DeviceTDCS sham-stimulation

    TDCS sham-stimulation

06

What researchers measure

Primary outcomes

  1. Number of participants with status epilepticus termination between tDCS treatment group and tDCS sham--stimulation group as assessed by Salzburg Consensus Criteria for Non-Convulsive Status Epilepticus

    Outcomes will be assessed by clinical observation and EEG evaluation before 10 times of tDCS stimulation between both groups

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Number of participants with treatment-related adverse events between tDCS treatment group and tDCS sham--stimulation group

    Treatment-emergent adverse events will be assessed by clinical observation between tDCS treatment group and tDCS sham--stimulation group

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Fisher RS, McGinn RJ, Von Stein EL, Wu TQ, Qing KY, Fogarty A, Razavi B, Venkatasubramanian C. Transcranial direct current stimulation for focal status epilepticus or lateralized periodic discharges in four patients in a critical care setting. Epilepsia. 2023 Apr;64(4):875-887. doi: 10.1111/epi.17514. Epub 2023 Feb 7. PubMed 36661376 ↗
  • Rezakhani S, Amiri M, Weckhuysen S, Keliris GA. Therapeutic efficacy of seizure onset zone-targeting high-definition cathodal tDCS in patients with drug-resistant focal epilepsy. Clin Neurophysiol. 2022 Apr;136:219-227. doi: 10.1016/j.clinph.2022.01.130. Epub 2022 Feb 3. PubMed 35217351 ↗

Individual participant data

Plan to share: No — This study is an exploratory study, and the important information is the signal analysis of electroencephalogram (EEG). However, these data were huge, which makes it difficult to export, save and upload. Meanwhile, the EEG data also require special softwares to read after being exported

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Oct 2026, 30 months after the start.

Of 22 interventional studies with no phase under Status Epilepticus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 65. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2024
First posted
Apr 3, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Oct 1, 2026
CompletionEst.
Oct 1, 2026
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06344338
Responsible party
Weibi Chen (associate professor, Xuanwu Hospital, Beijing) — Principal investigator
First posted
Apr 3, 2024
Start date
Apr 1, 2024
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Aug 4, 2026

Study contacts

research centre of Xuanwu hospital Capital Medical University
Contact
liugangqingyi@sina.com
+8601083198899 ext. 8270
Jiaqing Tian, Dr
Contact
smile21tian@163.com
+8615311415116
Weibi Chen, Dr
study director · Xuanwu Hospital, Beijing
Jiaqing Yan, Dr
principal investigator · College of Electrical and Control Engineering, North China University of Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion